PFIZER INC Disposal Group, Including Discontinued Operation, Liabilities, Current
PFIZER INC (PFE) had Disposal Group, Including Discontinued Operation, Liabilities, Current of $0 as of 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Balance Sheet › Liabilities
us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent · last filed 2021-02-25
- 2020-12-31: Disposal Group, Including Discontinued Operation, Liabilities, Current $0.00.
- 2019-12-31: Disposal Group, Including Discontinued Operation, Liabilities, Current $2.41B.
- 2013-12-31: Disposal Group, Including Discontinued Operation, Liabilities, Current $21.00M.
- 2013-09-29: Disposal Group, Including Discontinued Operation, Liabilities, Current $21.00M.
| Period end | Disposal Group, Including Discontinued Operation, Liabilities, Current | Disposal Group, Including Discontinued Operation, Liabilities, Current as first filed |
|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 | |
| 2019-12-31 | $2.41B 10-K · filed 2021-02-25 | |
| 2013-12-31 | $21.00M 10-K · filed 2014-02-28 | |
| 2013-09-29 | $21.00M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $0.00 10-Q · filed 2013-08-09 | |
| 2012-12-31 | $874.00M 10-K · filed 2014-02-28 | $0.00 10-K · filed 2013-02-28 |
| 2012-09-30 | $554.00M 10-Q · filed 2012-11-09 | |
| 2012-07-01 | $427.00M 10-Q · filed 2012-08-09 | |
| 2011-12-31 | $385.00M 10-K · filed 2013-02-28 | |
| 2011-04-03 | $133.00M 10-Q · filed 2011-05-12 | |
| 2010-12-31 | $124.00M 10-Q · filed 2011-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |